Publication:
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial

Suggested Citation

Aditya H. Gaur, Mark F. Cotton, Carina A. Rodriguez, Eric J. McGrath, Elizabeth Helström, Afaaf Liberty, Eva Natukunda, Pope Kosalaraksa, Kulkanya Chokephaibulkit, Heather Maxwell, Pamela Wong, Danielle Porter, Sophia Majeed, Mun Sang Yue, Hiba Graham, Hal Martin, Diana M. Brainard, Cheryl Pikora Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. The Lancet Child and Adolescent Health. Vol.5, No.9 (2021), 642-651. doi:10.1016/S2352-4642(21)00165-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77890

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Availability

Collections